What is Tesamorelin?

Tesamorelin is a synthetic analog of GHRH — growth hormone-releasing hormone — engineered for greater stability and potency than natural GHRH. It was FDA-approved in 2010 under the brand name Egrifta for the treatment of HIV-associated lipodystrophy (excess belly fat caused by antiretroviral therapy), making it one of the only peptides with full FDA drug approval.

Unlike Sermorelin and CJC-1295, Tesamorelin was designed specifically to target visceral adipose tissue (the deep belly fat surrounding organs) while preserving lean muscle mass. This selective effect on fat distribution — without the insulin resistance risks associated with synthetic HGH — has made it highly attractive for off-label use in metabolic optimization and anti-aging protocols.

Key advantage over synthetic HGH: Tesamorelin works within the body’s natural GH feedback loop, preserving pituitary function and avoiding the suppression and side effects associated with direct GH replacement. It produces consistent visceral fat reduction with a significantly better safety profile.

Key benefits of Tesamorelin

Here is what the research and clinical experience suggest Tesamorelin can do:

Visceral fat reduction

Clinically proven to reduce visceral (abdominal) fat by 15–20% — more effectively than any other non-surgical intervention.

Lean mass preservation

Reduces fat without significant muscle loss — a key advantage over caloric restriction alone.

Improved metabolic markers

Reduces triglycerides and improves insulin sensitivity, with cardiovascular benefits in higher-risk populations.

Cognitive function

Emerging research suggests Tesamorelin may improve executive function and memory in older adults.

GH optimization

Restores youthful GH pulsatility without suppressing the pituitary or requiring synthetic hormone replacement.

IGF-1 increase

Elevates IGF-1 levels, which supports tissue repair, muscle maintenance, and bone density.

How does Tesamorelin work?

GHRH receptor binding

Tesamorelin binds to GHRH receptors on pituitary somatotrophs, stimulating synthesis and release of HGH in a pulsatile pattern that mirrors the body’s natural rhythm. This physiological release pattern is healthier than the flat, constant levels produced by synthetic HGH injections.

Selective fat mobilization

The elevated GH triggered by Tesamorelin activates lipolysis preferentially in visceral adipose tissue. The mechanism is not fully understood, but Tesamorelin’s visceral-fat-specific effect is more pronounced than that of other GHRH analogs — likely due to differences in receptor distribution and downstream signaling in visceral vs subcutaneous fat cells.

IGF-1 upregulation

Elevated GH levels trigger the liver to produce more IGF-1, which mediates many of GH’s anabolic and restorative effects throughout the body — including in muscle, bone, and connective tissue.

Dosing guide

Dosing varies depending on your goal and method of administration. Always work with a licensed provider to determine your specific protocol.

GoalTypical doseFrequencyMethod
Visceral fat reduction1–2 mgOnce daily at bedtimeSubcutaneous injection
Body composition1 mgOnce daily at bedtimeSubcutaneous injection
Anti-aging (off-label)1 mg5 days on / 2 offSubcutaneous injection
Stacked with Ipamorelin1 mg Tesa + 200 mcg IpaDaily or 5x/weekSubcutaneous injection

Important: Dosing information here is educational only. The right protocol for you depends on your health history, goals, and body weight. A licensed clinic can prescribe and supervise your treatment safely.

Side effects & safety

Tesamorelin has one of the best-documented safety profiles of any GHRH peptide, given its FDA-approved status and extensive clinical trial data. Side effects are generally mild and manageable.

Possible side effects include: Injection site reactions (redness, pain, bruising), fluid retention especially in early treatment, joint aches, and occasional nausea. These typically improve after the first few weeks of treatment as the body adjusts.

Unlike synthetic HGH, Tesamorelin does not significantly increase fasting glucose or worsen insulin resistance at standard doses — a key safety advantage for metabolically compromised patients. Patients with active malignancy should not use Tesamorelin.

Related guides: Sermorelin overview | Sermorelin vs HGH | CJC-1295 overview

Frequently asked questions

Is Tesamorelin FDA-approved?
Yes — Tesamorelin is FDA-approved under the brand name Egrifta specifically for HIV-associated lipodystrophy. Off-label use for body composition and anti-aging in HIV-negative patients is common but requires a prescription from a licensed physician who can assess whether it is appropriate for your situation.
How does Tesamorelin compare to Sermorelin?
Both are GHRH analogs that stimulate natural GH production. Tesamorelin is more potent, has a longer half-life, and is specifically effective for visceral fat reduction. Sermorelin has a longer clinical track record and FDA approval for different indications. For body composition and fat loss specifically, Tesamorelin tends to be preferred; for general anti-aging, either can be appropriate.
How long does it take to see fat loss with Tesamorelin?
Clinical trials showed significant visceral fat reduction after 26 weeks of daily use — with measurable changes beginning around weeks 8–12. Most patients notice improved body composition (waist circumference, belly definition) within 3 months. Results are best when combined with appropriate nutrition and exercise.
Is Tesamorelin safe for people without HIV?
The clinical data on Tesamorelin in HIV-negative populations is more limited than in HIV patients, but off-label use is well-established in functional medicine. Most providers consider it safe and effective for appropriate candidates based on available evidence. A proper medical evaluation is essential before starting.
How do I get a Tesamorelin prescription?
Tesamorelin requires a prescription from a licensed physician. Functional medicine and hormone optimization clinics are the most common prescribers for off-label anti-aging use. Tides connects you with vetted providers — join the waitlist to get matched with a clinic near you.